Article Text

PDF
SP0121 Long term side effects of biological agents in jia
  1. JF Swart,
  2. on behalf of Pharmachild and Foreum (Comorbidity in JIA)
  1. Pediatric Rheumatology, UMC Utrecht, Utrecht, Netherlands

Abstract

In the last years, the interest in the concept of comorbidity and its societal as well as individual impact has increased. Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease starting in childhood which often persists into adulthood. Clinicians are facing an aging population with multiple morbid conditions occurring in one individual. Long term outcome studies show the high prevalence and the potential interaction of coexisting diseases. For JIA recent studies reported that uveitis, asthma/atopic diseases and diabetes mellitus are prevalent comorbidities in JIA with 11.6–30%, 10.8% and 3.5% respectively, followed by cardiovascular disease, malignancies and inflammatory bowel diseases. Childhood long term outcome studies and Pharmacovigilance registries already revealed associations of co-existing diseases and the role of used medication (especially biologicals). It is important to plan preventive and screening strategies in order to prevent or early detect and treat comorbidities and integrated follow up once comorbidity exists.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.